BIOMAT Database Logo BIOMAT Database Logo

Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and its variant, androgen receptor-variant 7. 2023

Balaji Chandrasekaran, and Ashish Tyagi, and Uttara Saran, and Venkatesh Kolluru, and Becca V Baby, and Venkat R Chirasani, and Nikolay V Dokholyan, and Jyh M Lin, and Amandeep Singh, and Arun K Sharma, and Murali K Ankem, and Chendil Damodaran
Department of Pharmaceutical Science, College of Pharmacy, Texas A&M University, College Station, TX, United States.

We investigated the efficacy of a small molecule ASR-600, an analog of Urolithin A (Uro A), on blocking androgen receptor (AR) and its splice variant AR-variant 7 (AR-V7) signaling in castration-resistant prostate cancer (CRPC). ASR-600 effectively suppressed the growth of AR+ CRPC cells by inhibiting AR and AR-V7 expressions; no effect was seen in AR- CRPC and normal prostate epithelial cells. Biomolecular interaction assays revealed ASR-600 binds to the N-terminal domain of AR, which was further confirmed by immunoblot and subcellular localization studies. Molecular studies suggested that ASR-600 promotes the ubiquitination of AR and AR-V7 resulting in the inhibition of AR signaling. Microsomal and plasma stability studies suggest that ASR-600 is stable, and its oral administration inhibits tumor growth in CRPC xenografted castrated and non-castrated mice. In conclusion, our data suggest that ASR-600 enhances AR ubiquitination in both AR+ and AR-V7 CRPC cells and inhibits their growth in vitro and in vivo models.

UI MeSH Term Description Entries

Related Publications

Balaji Chandrasekaran, and Ashish Tyagi, and Uttara Saran, and Venkatesh Kolluru, and Becca V Baby, and Venkat R Chirasani, and Nikolay V Dokholyan, and Jyh M Lin, and Amandeep Singh, and Arun K Sharma, and Murali K Ankem, and Chendil Damodaran
PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells.
January 2021, International journal of biological sciences,
Balaji Chandrasekaran, and Ashish Tyagi, and Uttara Saran, and Venkatesh Kolluru, and Becca V Baby, and Venkat R Chirasani, and Nikolay V Dokholyan, and Jyh M Lin, and Amandeep Singh, and Arun K Sharma, and Murali K Ankem, and Chendil Damodaran
Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.
August 2016, International journal of urology : official journal of the Japanese Urological Association,
Balaji Chandrasekaran, and Ashish Tyagi, and Uttara Saran, and Venkatesh Kolluru, and Becca V Baby, and Venkat R Chirasani, and Nikolay V Dokholyan, and Jyh M Lin, and Amandeep Singh, and Arun K Sharma, and Murali K Ankem, and Chendil Damodaran
Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer.
August 2020, Carcinogenesis,
Balaji Chandrasekaran, and Ashish Tyagi, and Uttara Saran, and Venkatesh Kolluru, and Becca V Baby, and Venkat R Chirasani, and Nikolay V Dokholyan, and Jyh M Lin, and Amandeep Singh, and Arun K Sharma, and Murali K Ankem, and Chendil Damodaran
Targeting the Androgen Receptor by Taxol in Castration-Resistant Prostate Cancer.
January 2010, Molecular and cellular pharmacology,
Balaji Chandrasekaran, and Ashish Tyagi, and Uttara Saran, and Venkatesh Kolluru, and Becca V Baby, and Venkat R Chirasani, and Nikolay V Dokholyan, and Jyh M Lin, and Amandeep Singh, and Arun K Sharma, and Murali K Ankem, and Chendil Damodaran
Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
September 2016, Clinical cancer research : an official journal of the American Association for Cancer Research,
Balaji Chandrasekaran, and Ashish Tyagi, and Uttara Saran, and Venkatesh Kolluru, and Becca V Baby, and Venkat R Chirasani, and Nikolay V Dokholyan, and Jyh M Lin, and Amandeep Singh, and Arun K Sharma, and Murali K Ankem, and Chendil Damodaran
Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.
December 2016, Oncogene,
Balaji Chandrasekaran, and Ashish Tyagi, and Uttara Saran, and Venkatesh Kolluru, and Becca V Baby, and Venkat R Chirasani, and Nikolay V Dokholyan, and Jyh M Lin, and Amandeep Singh, and Arun K Sharma, and Murali K Ankem, and Chendil Damodaran
Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
February 2014, Future oncology (London, England),
Balaji Chandrasekaran, and Ashish Tyagi, and Uttara Saran, and Venkatesh Kolluru, and Becca V Baby, and Venkat R Chirasani, and Nikolay V Dokholyan, and Jyh M Lin, and Amandeep Singh, and Arun K Sharma, and Murali K Ankem, and Chendil Damodaran
Androgen Receptor and Beyond, Targeting Androgen Signaling in Castration-Resistant Prostate Cancer.
January 2016, Cancer journal (Sudbury, Mass.),
Balaji Chandrasekaran, and Ashish Tyagi, and Uttara Saran, and Venkatesh Kolluru, and Becca V Baby, and Venkat R Chirasani, and Nikolay V Dokholyan, and Jyh M Lin, and Amandeep Singh, and Arun K Sharma, and Murali K Ankem, and Chendil Damodaran
Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
May 2016, Medical oncology (Northwood, London, England),
Balaji Chandrasekaran, and Ashish Tyagi, and Uttara Saran, and Venkatesh Kolluru, and Becca V Baby, and Venkat R Chirasani, and Nikolay V Dokholyan, and Jyh M Lin, and Amandeep Singh, and Arun K Sharma, and Murali K Ankem, and Chendil Damodaran
Urinary exosome-based androgen receptor-variant 7 detection in metastatic castration-resistant prostate cancer patients.
February 2022, Translational andrology and urology,
Copied contents to your clipboard!